| 2.39 0.45 (23.2%) | 08-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.58 |
1-year : | 4.41 |
| Resists | First : | 3.06 |
Second : | 3.77 |
| Pivot price | 2.48  |
|||
| Supports | First : | 1.9 |
Second : | 1.58 |
| MAs | MA(5) : | 2.14 |
MA(20) : | 2.56 |
| MA(100) : | 2.75 |
MA(250) : | 7.08 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 4.7 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 21.2 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LNAI ] has closed above bottom band by 43.1%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.78 - 3.8 | 3.8 - 3.83 |
| Low: | 1.88 - 1.9 | 1.9 - 1.91 |
| Close: | 2.36 - 2.39 | 2.39 - 2.41 |
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology.
Thu, 30 Jul 2026
Why Is LNAI Stock Skyrocketing Today? - Stocktwits
Wed, 29 Jul 2026
LNAI: Lunai Bioworks Inc. - Financial Overview - Zacks Investment Research
Sat, 27 Jun 2026
Enterprise value to revenue forward of Lunai Bioworks Inc. – NASDAQ:LNAI - tradingview.com
Wed, 17 Jun 2026
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS - PR Newswire
Wed, 17 Jun 2026
Lunai Bioworks touts defense revenue, neurology pipeline, lawsuit - Stock Titan
Wed, 17 Jun 2026
Lunai Bioworks Inc. Reports Material Event | LNAI Form 8-K - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.17e+006 (%) |
| Held by Institutions | 40.7 (%) |
| Shares Short | 287 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.77e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 815.2 % |
| Return on Equity (ttm) | -9.7 % |
| Qtrly Rev. Growth | 20940 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -929.89 |
| EBITDA (p.s.) | 59828.6 |
| Qtrly Earnings Growth | -61.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.4 |
| Dividend | 0 |
| Forward Dividend | 121750 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|